Whalesbook
Elara Capital Initiates Coverage on Sagility
Elara Capital has begun covering Sagility, a healthcare technology and operations firm, with a 'Buy' rating and a ₹54 price target. This valuation implies approximately 26% potential upside from the stock's closing price on April 17, 2026. Elara's optimistic view stems from Sagility's position to benefit from ongoing cost pressures faced by healthcare payers. These pressures are boosting demand for outsourcing and expanded services across the payer industry. Sagility's strong client relationships, with an average tenure of 18 years for its top five clients, indicate a deep capacity for growth and retention within these accounts.
Key Drivers for Sagility's Growth
Sagility stands to gain as healthcare payers face rising operational expenses and increasing Medical Loss Ratios (MLRs). Over the past decade, administrative costs for payers have grown at a compound annual growth rate of 2.5% to 18%. Concurrently, rising MLRs, a metric reflecting the proportion of premiums spent on claims and quality improvement, are compelling payers to seek efficiency through outsourcing. Major payers like United Healthcare, Humana, and CVS Aetna are facing these pressures, creating an ideal environment for service providers like Sagility. Sagility has guided for 22.5% revenue growth in FY26 and expects mid-to-high teen growth medium-term, a path Elara Capital sees as achievable.
Growth Potential and Margin Outlook
Elara Capital sees substantial growth potential within Sagility's largest client accounts. Revenue from its top five clients, totaling $550 million as of the trailing twelve months ending December 2025, could scale by 80-90%, particularly from clients 3, 4, and 5. The top three clients, generating $465 million, offer a further 40% scaling opportunity. Elara forecasts revenue and earnings CAGRs of 13.9% and 20.0% in INR terms, respectively, for FY26E-FY28E. Adjusted EBITDA margins are expected to face pressure in FY26 due to integrating the lower-margin Broadpath business but are projected to stabilize around 25% by FY28. Earnings are expected to accelerate in FY28, helped by planned debt repayment in FY27, which will remove finance costs.
Industry Trends and Valuation
The healthcare IT outsourcing market is growing rapidly, fueled by digitalization, AI adoption, and the demand for value-based care. Projections suggest the global market will grow significantly, with North America remaining the largest market. Sagility competes within this expanding sector, facing players like EXL Service and WNS Global Services. Sagility's current P/E ratio of about 22-23x FY28E EPS is competitive. Some analysts view it as undervalued against peers, while others see it as trading at a premium or expensive based on historical averages or industry benchmarks. Despite recent downgrades by some analysts to 'Hold' due to technicals and valuation, Elara Capital sees Sagility's valuation at 15.2x FY28E EPS as a discount to peers. Elara believes client concentration risks are overstated. The company's projected FY26 revenue growth of over 20%, including Broadpath, is supported by both organic momentum and strategic acquisitions.
Key Risks and Challenges
Client concentration remains a concern, with 60% to 85% of revenue coming from its top 3, 5, and 10 clients. A major client leaving could significantly impact financial performance. Integrating Broadpath, acquired in early 2025, is expected to reduce EBITDA margins by up to 150 basis points in FY26 due to its lower margins and integration costs. Although management aims to offset this with synergies and standardization, ongoing margin pressure is possible. The company's operations are closely tied to U.S. healthcare regulations like the Affordable Care Act and Medicare policies, making it vulnerable to legislative changes affecting payer budgets. The rapid advancement of generative AI also poses a potential long-term risk, as it could automate services currently outsourced to Sagility. Sagility's returns on equity (7.38%) and capital employed (9.58%) lag industry averages, and its promoter holding has decreased. However, it has reduced debt, with a planned repayment in FY27.
Analyst Consensus and Future Prospects
Elara Capital's ₹54 target price values Sagility at 19x FY28E EPS, expecting strong earnings growth to drive a stock re-rating. This aligns with a generally positive analyst consensus, with average price targets near ₹58, suggesting significant upside. However, some analysts have maintained higher targets, such as Motilal Oswal at INR 66 and Jefferies at INR 64, reflecting differing valuation methodologies and growth assumptions. Sagility has guided for 22.5% revenue growth in FY26 and projects low-to-mid teen growth over the medium term. The Broadpath acquisition is expected to boost Sagility's long-term growth, reduce client concentration, and enhance its onshore presence, with some analysts seeing limited integration risks.